Research Article

Early Identification of High-Risk Factors for Upper Gastrointestinal Bleeding

Xuesong Jin, Xiaohong Wang, and Pengfei Mao

Department of Gastroenterology, Suzhou Hospital of Integrated Traditional Chinese and Western Medicine, Jiangsu 215101, China

Correspondence should be addressed to Pengfei Mao; mpf202206@163.com

Received 14 July 2022; Revised 11 September 2022; Accepted 19 September 2022; Published 13 October 2022

Academic Editor: Peng-Yue Zhang

Copyright © 2022 Xuesong Jin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. To identify simple and accurate pre-endoscopy risk factors for early identification of high-risk upper gastrointestinal bleeding. Methods. Patients who were admitted to Suzhou Hospital of Integrated Traditional Chinese and Western Medicine from January 1, 2016, to December 31, 2019, due to upper gastrointestinal bleeding were retrieved, and the detailed clinical data of the above patients were collected. Patients with a definite diagnosis of bleeding from esophageal and gastric varices were assigned to the high-risk group. Patients with bleeding not caused by varices were divided into a high-risk and a low-risk group according to the Forrest grading and scoring standard (high-risk group Forrest Ia-IIb, low-risk group Forrest IIc-III). Univariate analysis, t-test, chi-square test, binary logistic regression, ROC curve (Receiver-operating characteristic curve), etc. were employed for analysis in order to identify some simple and accurate risk factors for high-risk upper digestion tract bleeding before endoscopy. Results. A total of 916 patients were collected. Three risk factors among the screened risk factors (1) hemoglobin $\leq 85\text{g/L}$, (2) vomiting red blood, and (3) "red bloody stool" were analyzed by ROC curve analysis. The specificities of each factor were 78.4%, 94.5%, and 96.7%, respectively, and the sensitivities were 71.8%, 55.9%, and 23.1%, respectively. We also derived a risk prediction scoring system for the three factors that meet the high risk such as (1) hemoglobin $\leq 83\text{g/L}$, (2) vomiting red blood, and (3) "red bloody stool." The area under the ROC curve (AUROC), sensitivity, and specificity were 0.877, 0.904, and 0.746. Conclusion. Hemoglobin $\leq 85\text{g/L}$, vomiting red blood, and red bloody stool were included in a simple scoring standard for predicting high-risk UGIB patients before endoscopy. The new risk prediction scoring system requires only three indicators and has the advantages of high accuracy, short time-consuming, and easy application.

1. Introduction

Acute upper gastrointestinal bleeding (AUGIB) refers to the bleeding above the ligament of Trevar’s, the main clinical manifestations are hematemesis, melena, etc. It is a common and potentially life-threatening emergency clinical disease. Its annual incidence rate is (100–180)/100,000 [1]. Among them, nonvariceal upper gastrointestinal bleeding accounts for the vast majority, about 80%–90%, and variceal bleeding accounts for about 10% [2]. Although variceal bleeding is a minority among all upper gastrointestinal bleeding (UGIBs), it has a high mortality rate of 30 percent in initial hospitalization, nearly 60 percent within 1 year [3], and rebleeding occurs in 70 percent of patients [4]. In patients with nonvariceal bleeding such as high-risk ulcer Forrest Ia, the rebleeding rate is as high as 90% [5]. The management and timing of endoscopy in patients with high-risk conditions in UGIB differs from other patients because it predicts higher rates of rebleeding and mortality [6]. Therefore, risk stratification is important for determining treatment indications and predicting clinical outcomes, and early identification of high-risk patients is essential for intensive treatment and early intervention. At present, many studies have shown that endoscopy is key to the diagnosis of upper gastrointestinal bleeding, and it is also the gold standard for identifying active bleeding. Drug combined with endoscopy is now the preferred treatment, no matter in variceal bleeding or nonvariceal bleeding [7, 8]. More studies have shown that advanced endoscopic therapy can significantly reduce the rebleeding rate and mortality of patients with...
gastrointestinal bleeding, and improve the prognosis of patients [9]. Currently widely accepted pre-endoscopy scoring systems are Glasgow Blatchford Score (GBS), Rockall Score (RS), and AIMS65. Among them, GBS has a high predictive value in terms of intervention and mortality [10]. However, these criteria are complicated to calculate or need to be completed after endoscopy before further evaluation, making it difficult to apply them clinically. A study found that only about 50% of the surveyed 1,000 related doctors knew about these scoring systems, and 30% of them had used one of these scoring systems for patients with UGIB [11]. To date, there is no universally agreed scoring standard for predicting high-risk upper gastrointestinal bleeding populations, and the existing scoring systems have not been updated to adapt to changes in clinical characteristics. Our purpose is to screen out high-risk UGIB patients using a more accurate, simple, and convenient scoring standard, which reminds clinicians to take the next step of diagnosis and treatment as soon as possible.

2. Materials and Methods

Admitted patients were retrieved from the Gastroenterology Department of Suzhou Integrated Traditional Chinese and Western Medicine Hospital from September 1, 2016, to September 30, 2018. The included patients should have symptoms of acute hematemesis or melena, with the gastroscopy-confirmed presence of explainable lesions leading to upper gastrointestinal bleeding. Endoscopy should be completed within 24–48 hours after admission. Exclude patients who were unwilling to take endoscopy or had malignant diseases, hematological disorders, mental illness, drug allergies, etc.

Detailed medical history, such as cardiovascular and cerebrovascular diseases, liver cirrhosis, hypertension, diabetes, recent drug (NSAIDs, hormone drugs) taking history, etc. were collected. Clinical manifestations included the color of hematemesis, the color of stool, cold sweat, palpititation, and syncope. Vital signs included systolic blood pressure, diastolic blood pressure, and heart rate.

The laboratory data of UGIB patients within 48 hours of hematemesis or melena were collected for analysis, including prothrombin time (PT), activated partial thrombin time (APTT), hemoglobin (Hb), hematocrit (MCV), the lowest value of platelet count (PLT), the highest value of blood urea nitrogen (BUN), and serum creatinine (Scr).

Endoscopy results: gastroscopy should be performed within 24–48 hours after symptoms appear, and those with peripheral circulatory failure should be corrected first. Endoscopy includes evidence of esophageal and gastric variceal bleeding such as (1) active bleeding from varices; (2) “white papilla” overlying varices; and (3) variceal overlying blood clots or no other Varicose veins that are the underlying cause of bleeding. For nonvariceal bleeding, the Forrest grading scale was used. All endoscopic diagnostic criteria were jointly decided by three endoscopists. Patients were treated according to the consensus of the Asia-Pacific Working Group recommended by the international consensus [12]. The standard of care is as follows: start PPIs like pantoprazole, omeprazole, and esomeprazole for all patients with upper GI bleeding who are admitted to the hospital. Blood transfusion is required in the following situations: the patient presents with unstable hemodynamics, such as systolic blood pressure <90 mmHg, heart rate >120 beats/min, and hemoglobin < 70 g/L. Principles of endoscopic treatment: the treatment of acute esophageal variceal bleeding (EVB) mainly includes conservative drug administration, endoscopic treatment, balloon tamponade, transjugular intrahepatic portal shunt (TIPS), and surgical treatment [13]. For nonvariceal upper gastrointestinal bleeding, submucosal injection of epinephrine, electrocoagulation, titanium clips, or a combination of these methods are used alone. Patients with esophageal and gastric varices are treated with endoscopic band ligation, tissue adhesive injection, combined treatment with multiple methods, and interventional surgery, which depends on the judgment of the endoscopic surgeon [14].

2.1. Statistical Methods. SPSS17.0 (Armonk, NY) was used for statistical analysis and processing of data. The description of measurement data was performed by mean± standard deviation (X± SD), and the description of categorical variable data was performed by percentage. Univariate factor analysis was performed for measurement data using an independent samples t-test, and the chi-square test was used for categorical variable data. The factors with significant significance between the two groups of data were included in the binary logistic regression analysis, and the relevant high-risk factors were obtained. Then the obtained high-risk factors were combined to establish a regression equation model (inclusion level 0.05, exclusion level 0.10). The independent risk factors screened above were compared individually and also in combination. Statistically significant was set at a two-sided P< 0.05.

3. Results

3.1. Clinical Characteristics of 916 UGIB Patients. A total of 1079 UGIB patients were retrieved, of which 108 patients underwent endoscopic examination more than 48 hours beyond the initial bleeding, 53 patients had chronic anemia, and 2 patients had bleeding in other parts of the upper gastrointestinal tract (1 patient with biliary bleeding, 1 patient with pancreatic cancer involving duodenum hemorrhage). The remaining 916 patients with upper gastrointestinal bleeding were included in this study, and 372 patients were at high risk according to the Forrest classification, accounting for 40.61% of the study population. Among them, there were 17 Forrest Ia patients (4.57%); 56 Forrest Ib patients (15.05%); 205 Forrest IIa patients (55.11%), and 94 Forrest IIb patients (25.27%). There were 425 low-risk patients, accounting for 46.39% of the study population, including 74 Forrest IIIa patients (8.08%) and 351 Forrest IIIb patients (34.39%). There were 119 patients with EVB bleeding, accounting for 12.99% of the study population. Due to the high recurrence rate and mortality rate of
bleeding caused by EVB [15, 16], they were all included in the high-risk group. In summary, there were 491 patients in the high-risk group and 425 in the low-risk group. The average age of the patients was 57.13 ± 17.31 years old in the high-risk group, and 52.54 ± 18.19 years old in the low-risk group (P < 0.05). The ratio of males to females was 195:296 in the high-risk group, and 112:313 in the low-risk group (P < 0.05), as shown in Table 1. The etiology of UGIB in this study included peptic ulcer in 813 cases (88.76%), a gastrointestinal tumor in 33 cases (3.60%), dieulafoy ulcer in 14 cases (1.53%), acute erosive hemorrhagic gastritis in 11 cases (1.20%), and cardiac tear in 45 cases (4.91%).

Among the 916 patients, there were significant differences between the two groups in terms of previous underlying diseases, non-steroidal anti-inflammatory drugs use, hepatitis, liver cirrhosis, and hypertension (P < 0.05). Clinical manifestations include "vomiting red blood, red bloody stools, and shock," "diastolic blood pressure in vital signs, and "prothrombin time, activated partial thromboplastin time, hemoglobin, hematocrit" in laboratory hematology indexes, platelet count, albumin," which had statistical differences between the two groups (P < 0.05). It is suggested that the above 16 indicators may be meaningful for predicting high-risk UGIB patients. The 16 factors were further analyzed below, and the specific data are shown in Table 1.

### Table 1: Clinical characteristics of 916 UGIB patients.

| Clinical factors                              | Low risk (n = 425) | High risk (n = 491) | P   |
|-----------------------------------------------|-------------------|---------------------|-----|
| Gender, male                                  | 112 (26.35%)      | 195 (39.71%)        | <0.001 |
| Age, y                                        | 52.54±18.19       | 57.13±17.31         | <0.001 |
| SBP (mmHg)                                    | 121±17.37         | 119.32±20.85        | 0.083 |
| DBP (mmHg)                                    | 73.55±11.32       | 69.00±12.54         | <0.001 |
| HR (beat/min)                                 | 85.12±14.06       | 83.93±16.92         | 0.077 |
| Hb (g/L)                                      | 100.49±21.88      | 73.63±20.71         | <0.001 |
| HCT (%)                                       | 30.09±6.73        | 22.73±6.12          | <0.001 |
| PLT (× 109)                                   | 198.26±61.33      | 151.40±81.45        | <0.001 |
| PT (s)                                        | 13.62±2.35        | 15.22±2.94          | <0.001 |
| APTT (s)                                      | 32.38±9.21        | 34.69±7.81          | <0.001 |
| Albumin (g/L)                                 | 36.68±5.34        | 31.06±9.52          | <0.001 |
| BUN (mmol/L)                                  | 10.29±6.79        | 11.95±3.14          | 0.115 |
| Cr (umol/L)                                   | 73.23±24.01       | 78.76±75.04         | 0.146 |
| NSAID                                         | 21.88%            | 15.89%              | 0.022 |
| Corticosteroids                               | 0.47%             | 1.63%               | 0.116 |
| Liver cirrhosis                               | 5.41%             | 18.33%              | <0.001 |
| Hypertension                                  | 31.16%            | 41.88%              | <0.001 |
| Hepatitis                                     | 2.11%             | 33.40%              | <0.001 |
| Diabetes mellitus                             | 13.65%            | 17.31%              | 0.144 |
| Cardiovascular diseases                       | 12.47%            | 10.79%              | 0.496 |
| Weight loss                                   | 4.24%             | 2.65%               | 0.203 |
| Red hematemesis                               | 6.36%             | 64.77%              | <0.001 |
| Red stool                                     | 3.76%             | 25.25%              | <0.001 |
| Palpation                                     | 48.71%            | 50.92%              | 0.508 |
| Cold sweat                                    | 42.12%            | 48.27%              | 0.063 |
| Syncope                                       | 16.00%            | 16.29%              | 0.928 |
| Shock                                         | 2.82%             | 12.83%              | <0.001 |

APTT = activated partial thromboplastin time; BUN = blood urea nitrogen; DBP = diastolic blood pressure; Hb = hemoglobin; HCT = hematocrit; HR = heart rate; NSAIDs = non-steroidal anti-inflammatory drugs; PLT = platelet cell; PT = prothrombin time; SBP = systolic blood pressure.

Further binary logistic analysis was performed on the 8 indicators of meaningful measurement variables of “age, diastolic blood pressure, prothrombin time, activated partial prothrombin time, hemoglobin, hematocrit, platelet count, albumin,” and only hemoglobin, hematocrit, platelet, prothrombin time, and albumin were statistically significant (P < 0.05), which were regarded as risk factors for high-risk UGIB patients, with odds ratios of 0.891, 1.259, 0.995, 1.112, and 0.963. Logit = 4.501 − 0.115 × hemoglobin + 0.230 × hematocrit − 0.005 × platelet + 0.106 × prothrombin time − 0.037 × albumin. The Cox and Snell R² was 0.328, and the Nagelkerke R² was 0.438 (Table 2).

### 3.3. Logistic and ROC Analysis of Clinical and Laboratory Characteristics for High-Risk UGIB Patients.

The 10 indicators of "gender, liver cirrhosis, vomiting of red blood, solution of red bloody stool, shock, hemoglobin, hematocrit, platelet, prothrombin time, and albumin" were combined and further analyzed, and the results showed that gender, shock, red blood cell pressure, the partial regression coefficients of blood clots, platelets, prothrombin time, and albumin were statistically significant (P < 0.05). Finally, three indicators of "liver cirrhosis, vomiting of red blood, solution of red bloody stool, and hemoglobin" were used as high-risk factors for predicting high-risk UGIB. The regression equation was: Logit = 2.136 + 0.081 × hemoglobin + 2.812 × vomiting red blood + 1.673 × relieving red bloody stool, Cox & Snell R² was 0.405, Nagelkerke R² was 0.550, and the detailed data are shown in Table 3.
Table 2: Logistic analysis of clinical and laboratory characteristics for high-risk UGIB patients.

| Characteristics                  | Equation                                                                 | Cox and Snell $R^2$ | Nagelkerke $R^2$ | Exp ($R^2$)                  | $P$          |
|----------------------------------|--------------------------------------------------------------------------|----------------------|------------------|-------------------------------|--------------|
| Sex                              | $-19.326 + 0.582 \times \text{sex} - 1.877 \times \text{cirrhosis} + 3.058 \times \text{hematemesis} + 2.215 \times \text{red stool} + 0.855 \times \text{shock}$ | 0.434               | 0.580            |                               | < 0.001      |
| NSAID                            |                                                                          |                      |                  |                               |              |
| Corticosteroids                  |                                                                          |                      |                  |                               |              |
| Hepatitis                        |                                                                          |                      |                  |                               |              |
| HBP                              |                                                                          |                      |                  |                               |              |
| Diabetes mellitus                |                                                                          |                      |                  |                               |              |
| Cardiovascular disease           |                                                                          |                      |                  |                               |              |
| Red hematemesis                  |                                                                          |                      |                  |                               |              |
| Red stool                        |                                                                          |                      |                  |                               |              |
| Weight loss                      |                                                                          |                      |                  |                               |              |
| Palpation                        |                                                                          |                      |                  |                               |              |
| Cold sweat                       |                                                                          |                      |                  |                               |              |
| Syncope                          |                                                                          |                      |                  |                               |              |
| Shock                            |                                                                          |                      |                  |                               |              |
| Age                              |                                                                          |                      |                  |                               |              |
| SBP                              |                                                                          |                      |                  |                               |              |
| DBP                              |                                                                          |                      |                  |                               |              |
| HR                               |                                                                          |                      |                  |                               |              |
| Hb                               |                                                                          |                      |                  |                               |              |
| HCT                              | $4.501 - 0.115 \times \text{Hb} + 0.230 \times \text{HCT} + 0.005 \times \text{PLT} + 0.106 \times \text{PT} - 0.037 \times \text{Albumin}$ | 0.328               | 0.438            |                               | < 0.001      |
| PLT                              |                                                                          |                      |                  |                               |              |
| PT                               |                                                                          |                      |                  |                               |              |
| APTT                             |                                                                          |                      |                  |                               |              |
| Albumin                          |                                                                          |                      |                  |                               |              |
| BUN                              |                                                                          |                      |                  |                               |              |

APTT = activated partial thromboplastin time; BUN = blood urea nitrogen; DBP = diastolic blood pressure; Hb = hemoglobin; HCT = hematocrit; HR = heart rate; NSAID = non-steroidal anti-inflammatory drug; PLT = platelet cell; PT = prothrombin time; SBP = systolic blood pressure.
The “hemoglobin” was used to make the ROC curve according to the risk level of VUGIB. The optimal critical value of hemoglobin was 85 g/L, and the specificity, sensitivity, positive likelihood ratio, negative likelihood ratio, Youden index, and AUROC were 0.772, 0.794, 0.608, 0.654, and 0.772, 0.651, 0.255, and 0.329, respectively. AUROC were 0.772, 0.794, 0.608, 0.654.

Table 3: Logistic analysis of clinical and laboratory characteristics for high-risk UGIB patients.

| Risk | β     | Exp (β) | P   | Cox & Snell R² | Nagelkerke R² |
|------|-------|---------|-----|----------------|---------------|
| Red hematemesis | 3.113 | 22.483 | < 0.001 | 0.4498 | 0.665 |
| Red stool | 1.795 | 6.020 | < 0.001 | 0.001 | 0.001 |
| Hb | −0.083 | 0.920 | < 0.001 | 0.4498 | 0.665 |
| Cirrhosis | 1.449 | 4.259 | 0.002 | 0.4498 | 0.665 |

* Hb = hemoglobin.

The Blatchford scoring system and the resulting new scoring system were evaluated by the ROC curve. See Figure 1 and Table 3 for details.

4. Discussion

UGIB refers to bleeding caused by diseases of the gastrointestinal tract above the ligament of Trevo, including pancreatic or bile duct bleeding and bleeding caused by diseases near the anastomotic stoma after gastrojejunostomy [15]. Due to advanced medical and endoscopic treatment, the hospitalization rate for upper gastrointestinal bleeding has decreased by 20% in the past decade, and the mortality rate has dropped from 4.5% to about 2.1%. Although the hospitalization rate and case fatality rate have decreased, the number of people is still larger for a larger population base. In fact, patients with variceal bleeding are considered a specific high-risk group [18]. Due to the high mortality rate and many complications of esophageal and gastric variceal bleeding, early identification of high-risk patients is extremely important, so it still has great research value.

In fact, patients with variceal bleeding are considered a specific high-risk group. A study by Cho SH [19] compared patients undergoing emergency endoscopy with regular gastroscopy, and there were significant differences in mortality, blood transfusion volume, and need for clinical intervention. Therefore, early identification of high-risk UGIB patients and early improvement of endoscopy can further improve the prognosis of patients. At present, a variety of scoring systems have been clinically used to assess the risk of upper gastrointestinal bleeding, each of which has different specificity, sensitivity, and predictive value for clinical observation indicators. The most commonly used risk assessment systems are the Forrest classification [20], BRS scoring standard, AIMS56 [21], and Rockall score, each of which has the characteristics of complex calculation and/or the need for endoscopy results, which makes the risk assessment system more complex for clinical application [20]. At present, researchers have proposed that accurate prediction of a series of risks in patients with UGIB is helpful for clinically selective management of these patients, and it is recommended that risk assessment should classify patients into high-risk and low-risk, because this may help clinicians make early decisions, such as the choice of endoscopy time, patient allocation, choice of level of care, and time to leave the hospital [22]. Early identification and evaluation of high-risk patients can improve the effectiveness of clinical treatment, shorten the time of treatment for patients, reduce the cost of treatment for patients, and improve clinical outcomes for patients.

Endoscopy is the key to diagnosing the etiology of upper gastrointestinal bleeding, and drug combined with endoscopy is now the preferred treatment [23]. Studies have shown that there is no solid basis for the benefit of earlier endoscopy. The Forrest classification has been used to identify high-risk endoscopic nonvariceal upper gastrointestinal bleeding. The Forrest grading is based on the results of endoscopy. Since the Forrest grading can better predict the risk of UGIB rebleeding, it can more intuitively
determine which UGIBs really need endoscopic intervention [24]. We took the Forrest classification as the gold standard for judging the severity of UGIB and divided UGIB patients into high-risk groups and low-risk groups according to the actual Forrest classification. The etiological analysis was consistent with the common etiology reported by the guideline [25]. We determined "hemoglobin" by ROC curve analysis, and the optimal critical value of hemoglobin was 83 g/L (see Table 4 and Figure 1(a) for details). Several clinical studies have suggested that hemoglobin between 80 and 85 g/L is a high-risk factor for acute upper gastrointestinal bleeding [5], and the conclusions drawn by our study were consistent with this. In the study of Forrest et al. [26], "vomiting bright red blood" was one of the high-risk indicators.

According to the correlation analysis by Zaragoza et al. [20], even after we excluded 33 participants who were classified as Forrest Ib, and through the aforementioned similar statistical methods, we still concluded that "(1) vomiting red blood, (2) red bloody stool, and (3) hemoglobin≤ 83 g/L" were three high-risk factors, and a new scoring system A.B.C and A.B.C were constructed to form two risk prediction scoring systems of score3 and score4, respectively. It can be seen from Figure 1(d) that among the two newly constructed risk prediction scoring systems, the risk prediction score 3 has the largest AUROC area of 0.871 when the critical value is 0.5, and the sensitivity, specificity, and Youden index were 89.8%, 75.4%, and 75.4%, respectively. When the critical value of scoring system 4 was 0.5, the AUROC area was 0.885, and the sensitivity, specificity, and Youden index were 92.0%, 74.6%, and 0.665, respectively. The Blatchford scoring system and the new scoring system were used to evaluate the ROC curve, and the

Figure 1: ROC curve of risk factors.
results showed that the above two scoring systems were better than BRS, score1, and score2 in evaluating patients with the high-risk nonvariceal upper gastrointestinal bleeding system. The value of our scoring system should be evaluated in severe cases, such as fulminant hepatitis, inflammation, infections, hypoxia, or preterm birth [27–37].

In conclusion, this study showed that “hemoglobin ≤ 83 g/L, vomiting red blood, and red bloody stool” could be three independent high-risk factors in patients with UGIB, while the combined application of these three risk factors can be a good way to screen high-risk UGIB patients before endoscopy.

**Data Availability**

The data used to support the findings of this study are available from the corresponding author upon request.

**Disclosure**

Xuesong Jin and Xiaohong Wang are the co-first authors.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.

**References**

[1] V. Jairath, B. C. Kahan, S. J. Stanworth et al., “Prevalence, management, and outcomes of patients with coagulopathy after acute nonvariceal upper gastrointestinal bleeding in the United Kingdom,” *Transfusion*, vol. 53, no. 5, pp. 1069–1076, 2013.

[2] I. Khamaysi and I. M. Gralnek, “Acute upper gastrointestinal bleeding (UGIB) - initial evaluation and management,” *Best Practice & Research Clinical Gastroenterology*, vol. 27, no. 5, pp. 633–638, 2013.
3. A. I. Sharara and D. C. Rockey, "Gastroesophageal variceal hemorrhage," *New England Journal of Medicine*, vol. 345, no. 9, pp. 669–681, 2001.

4. N. D. Grace, R. J. Groszmann, G. Garcia-Tsao et al., "Portal hypertension and variceal bleeding: an AASLD single topic symposium," *Hepatology*, vol. 28, no. 3, pp. 868–880, 1998.

5. L. Laine and D. M. Jensen, "Management of patients with ulcer bleeding," *American Journal of Gastroenterology*, vol. 107, no. 3, pp. 345–360, 2012.

6. G. I. Leontiadis, A. Sreedharan, S. Dorward et al., "Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding," *Health Technology Assessment*, vol. 11, no. 51, pp. 1–164, 2007.

7. S. A. Hearnshaw, R. F. A. Logan, D. Lowe, S. P. L. Travis, M. F. Murphy, and K. R. Palmer, "Use of endoscopy for management of acute upper gastrointestinal bleeding in the UK: results of a nationwide audit," *Gut*, vol. 59, no. 8, pp. 1022–1029, 2010.

8. Y. D. Kim, "Management of acute variceal bleeding," *Clinical Endoscopy*, vol. 47, no. 4, pp. 308–314, 2014.

9. E. J. Kuipers, "Improved risk assessment in upper GI bleeding," *Gastrointestinal Endoscopy*, vol. 74, no. 6, pp. 1225–1229, 2011.

10. A. J. Stanley, L. Laine, H. R. Dalton et al., "Comparison of risk scoring systems for patients resented with upper gastrointestinal bleeding: international multicenter prospective study," *BMJ*, vol. 356, 2017.

11. P. S. Liang, "A national survey on the initial management of upper gastrointestinal bleeding," *Journal of Clinical Gastroenterology*, vol. 48, pp. e93–e98, 2014.

12. N. C. Chavez-Tapia, T. Barrientos-Gutierrez, F. Tellez-Avila et al., "Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding—an updated Cochrane review," *Alimentary Pharmacology & Therapeutics*, vol. 34, no. 5, pp. 509–518, 2011.

13. M. A. Elsebaey, M. A. Tawfiq, S. Ezzat, A. Selim, H. Elashry, and S. Abd-Elalam, "Endoscopic injection sclerotherapy versus N-Butyl-2 Cyanoacrylate injection in the management of actively bleeding esophageal varices: a randomized controlled trial," *BMJ Gastroenterology*, vol. 19, no. 1, p. 23, 2019.

14. W. A. S. G. E. Qureshi, D. G. Adler, R. Davila et al., "ASGE Guideline: the role of endoscopy in the management of variceal hemorrhage," *Gastrointestinal Endoscopy*, vol. 62, no. 5, pp. 651–655, 2005.

15. A. J. Stanley, "Update on risk scoring systems for patients with upper gastrointestinal haemorrhage," *World Journal of Gastroenterology*, vol. 18, no. 22, pp. 2739–2744, 2012.

16. J. Golánová, L. Hrdlicka, J. Štovíček et al., "[Acute hemorrhage of the upper part of the gastrointestinal tract-survey of emergency endoscopy of the upper gastrointestinal tract at our facility]," *Vitriti Lékarství*, vol. 50, no. 4, pp. 274–277, 2004.

17. B. A. Wuerth and D. C. Rockey, "Changing epidemiology of upper gastrointestinal hemorrhage in the last decade: a nationwide analysis," *Digestive Diseases and Sciences*, vol. 63, no. 5, pp. 1286–1293, 2018.

18. M. S. Cappell, "Therapeutic endoscopy for acute upper gastrointestinal bleeding," *Nature Reviews Gastroenterology & Hepatology*, vol. 7, no. 4, pp. 214–229, 2010.

19. K. K. F. Tsoi, T. K. W. Ma, and J. J. Y. Sung, "Endoscopy for upper gastrointestinal bleeding: how urgent is it?" *Nature Reviews Gastroenterology & Hepatology*, vol. 6, no. 8, pp. 463–469, 2009.

20. A. M. Zaragoza, J. M. Tenias, M. J. Llorrente, and A. Alborch, "Prognostic factors in gastrointestinal bleeding due to peptic ulcer: construction of a predictive model," *Journal of Clinical Gastroenterology*, vol. 42, no. 7, pp. 786–790, 2008.

21. S. H. Cho, Y. S. Lee, Y. J. Kim et al., "Outcomes and role of urgent endoscopy in high-risk patients with acute nonvariceal gastrointestinal bleeding," *Clinical Gastroenterology and Hepatology*, vol. 16, no. 3, pp. 370–377, 2018.

22. O. Blatchford, W. R. Murray, and M. Blatchford, "A risk score to predict need for treatment for upper gastrointestinal haemorrhage," *The Lancet*, vol. 356, no. 9238, pp. 1318–1321, 2000.

23. J. R. Saltzman, Y. P. Tabak, B. H. Hyett, X. Sun, A. C. Travis, and R. S. Johannes, "A simple risk score accurately predicts in-hospital mortality, length of stay, and cost in acute upper GI bleeding," *Gastrointestinal Endoscopy*, vol. 74, no. 6, pp. 1215–1224, 2011.

24. T. A. Rockall, R. F. Logan, H. B. Devlin, and T. C. Northfield, "Risk assessment after acute upper gastrointestinal haemorrhage," *Gut*, vol. 38, no. 3, pp. 316–321, 1996.

25. P. S. Liang and J. R. Saltzman, "A national survey on the initial management of upper gastrointestinal bleeding," *Journal of Clinical Gastroenterology*, vol. 48, no. 10, pp. e93–e98, 2014.

26. J. A. Forrest, N. D. Finlayson, and D. J. Shearman, "Endoscopy in gastrointestinal bleeding," *The Lancet*, vol. 304, no. 7877, pp. 394–397, 1974.

27. Y. Yang, L. Deng, X. Li et al., "Analysis of prognosis-associated factors in fulminant viral hepatitis during pregnancy in China," *International Journal of Gynecology & Obstetrics*, vol. 114, no. 3, pp. 242–245, 2011.

28. L. Deng, X. Li, Z. Shi, P. Jiang, D. Chen, and L. Ma, "Maternal and perinatal outcome in cases of fulminant viral hepatitis in late pregnancy," *International Journal of Gynecology & Obstetrics*, vol. 119, no. 2, pp. 145–148, 2012.

29. Y. Yang, L. Deng, X. Li et al., "Evaluation of the prognosis of fulminant viral hepatitis in late pregnancy by the MELD scoring system," *European Journal of Clinical Microbiology & Infectious Diseases*, vol. 31, no. 10, pp. 2673–2678, 2012.

30. Y. Z. Bekmukhambetov, O. A. Mylnbaev, A. Tinelli et al., "Human Papillomavirus related issues in western Kazakhstan: protocol for a comprehensive study," *Russian Open Medical Journal*, vol. 7, no. 4, pp. e0408, 2018.

31. X. M. Li, L. Ma, Y. B. Yang, Z. J. Shi, and S. S. Zhou, "Prognostic factors of fulminant hepatitis in pregnancy," *Chinese Medical Journal*, vol. 118, no. 20, pp. 1754–1757, 2005.

32. Z. Shi, J. Vasquez-Vivar, K. Luo et al., "Ascending lipopolysaccharide-induced intrauterine inflammation in near-term rabbits leading to newborn neurobehavioral deficits," *Developmental Neuroscience*, vol. 40, no. 5-6, pp. 534–546, 2018.

33. J. Vasquez-Vivar, Z. Shi, J. W. Jeong et al., "Neuronal vulnerability to fetal hypoxia-reoxygenation injury and motor deficit development relies on regional brain tetrahydrobiopterin levels," *Redox Biology*, vol. 29, Article ID 101407, 2020.

34. Z. Shi, K. Luo, S. Jani et al., "Mimicking partial to total placental insufficiency in a rabbit model of cerebral palsy," *Journal of Neuroscience Research*, Article ID jnr24901, 2021.

35. J. Vasquez-Vivar, Z. Shi, K. Luo, K. Thirugnanam, and S. Tan, "Tetrahydrobiopterin in antenatal brain hypoxia-ischemia-induced motor impairments and cerebral palsy," *Redox Biology*, vol. 13, pp. 594–599, 2017.

36. Z. Shi, K. Luo, S. Deol, and S. Tan, "A systematic review of noninflammatory cerebrospinal fluid biomarkers for clinical
outcome in neonates with perinatal hypoxic brain injury that could be biologically significant,” *Journal of Neuroscience Research*, Article ID jnr.24801, 2021.

[37] X. Li, Y. Zhang, and Z. Shi, “Ritodrine in the treatment of preterm labour: a meta-analysis,” *Indian Journal of Medical Research*, vol. 121, no. 2, pp. 120–127, 2005.